News

Oxagen has completed the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its oral CRTH2 (DP2) antagonist. The study, which

Celgene has presented data for three Phase II studies evaluating combination therapy with Revlimid (lenalidomide) and Rituximab in patients with indolent non-hodgkin’s lymphoma (NHL) during the 51st American

Regenerx Biopharmaceuticals (Regenerx) has completed and analysed the safety data from its double-blind, placebo controlled Phase I clinical trial evaluating the systemic administration of RGN-352. RGN-352 is an

NanoMedex Pharmaceuticals (NanoMedex) was notified that it will be awarded a $2.23m Small Business Innovation Research (SBIR) Phase II Continuing Renewal grant from the National Institutes of Health

Skinvisible and Alto Pharmaceuticals (Alto) have entered into a license agreement for DermSafe, Skinvisible’s antimicrobial hand sanitiser lotion that recently completed clinical studies proving it kills the H1N1

Protalix has completed New Drug Application (NDA) submission with the FDA for Taliglucerase Alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of gaucher’s disease.

Sangart has initiated dose-finding study designed to evaluate the safety and efficacy of MP4OX treatment, plus standard of care, in severely injured trauma patients with lactic acidosis due

Sanofi-aventis has signed a strategic research alliance agreement with the California Institute of Technology (Caltech) in Pasadena, CA. The goal of the research collaboration, which will be known

Osteologix anticipates of filing a marketing application in 2011 in the EU for strontium therapy, NB S101 (Strontium Malonate). If successful, this is expected to be Osteologix’ first